Edition:
United States

Laboratory Corporation of America Holdings (LH.N)

LH.N on New York Stock Exchange

143.16USD
11:12am EST
Change (% chg)

$3.61 (+2.59%)
Prev Close
$139.55
Open
$140.60
Day's High
$143.27
Day's Low
$140.21
Volume
65,939
Avg. Vol
194,863
52-wk High
$190.35
52-wk Low
$136.21

Latest Key Developments (Source: Significant Developments)

Labcorp Sees 2018 Adj EPS Of $10.95 To $11.05
Friday, 30 Nov 2018 06:56am EST 

Nov 30 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP UPDATES FULL-YEAR 2018 GUIDANCE.LABCORP SEES 2018 ADJUSTED EPS $10.95 TO $11.05.LABCORP - SEES FY TOTAL REVENUE GROWTH 9.9% TO 10.3%.LABCORP SEES FY ADJUSTED EPS $10.95 TO $11.05.LABCORP SEES 2018 FREE CASH FLOW $940 MILLION TO $980 MILLION.LABCORP - LOOKING TO NEXT YEAR, CONTINUE TO EXPECT MODEST EPS GROWTH OVER UPDATED 2018 EARNINGS.LABCORP - COST REDUCTION INITIATIVES STATED IN Q3 CALL, WILL BE INSUFFICIENT TO MAINTAIN PRIOR OUTLOOK IN LIGHT OF UNANTICIPATED VOLUME SHORTFALL.LABCORP - REVISED OUTLOOK DRIVEN BY LOWER-THAN-EXPECTED VOLUME GROWTH IN LABCORP DIAGNOSTICS, WHICH CO BELIEVES WILL CONTINUE FOR REMAINDER OF YEAR.LABCORP - CONTINUE TO BE CONFIDENT IN OUTLOOK IN COVANCE DRUG DEVELOPMENT.FY2018 EARNINGS PER SHARE VIEW $11.35, REVENUE VIEW $11.39 BILLION -- REFINITIV IBES DATA.LABCORP - SOFTNESS IN DEMAND PRIMARILY DUE TO SLOWER GROWTH IN REFERRED DIRECT-TO-CONSUMER GENETIC TESTING, ADVERSE WEATHER, OTHERS.  Full Article

LabCorp At Walgreens Expands Into Southern California
Wednesday, 28 Nov 2018 08:45am EST 

Nov 28 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP AT WALGREENS EXPANDS INTO SOUTHERN CALIFORNIA.  Full Article

Labcorp Reports Q3 Adj EPS Of $2.74
Wednesday, 24 Oct 2018 06:50am EDT 

Oct 24 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP ANNOUNCES 2018 THIRD QUARTER RESULTS AND UPDATES 2018 GUIDANCE.Q3 EARNINGS PER SHARE $3.10.Q3 REVENUE $2.83 BILLION VERSUS I/B/E/S VIEW $2.84 BILLION.Q3 EARNINGS PER SHARE VIEW $2.88 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.25 TO $11.45.Q3 ADJUSTED EARNINGS PER SHARE $2.74.LABCORP - 2018 FREE CASH FLOW GUIDANCE OF $975 MILLION TO $1,025 MILLION.SEES FY18 REVENUE GROWTH OF 10.5% TO 11.0% OVER 2017 REVENUE OF $10.31 BILLION.BACKLOG AT QUARTER-END FOR COVANCE DRUG DEVELOPMENT WAS $9.40 BILLION COMPARED TO $8.97 BILLION LAST QUARTER.FY2018 EARNINGS PER SHARE VIEW $11.53 -- THOMSON REUTERS I/B/E/S.  Full Article

Labcorp Issued Statement On District Court Opinion In Acla Lawsuit Against HHS
Monday, 24 Sep 2018 07:10am EDT 

Sept 24 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP STATEMENT ON DISTRICT COURT OPINION IN ACLA LAWSUIT AGAINST HHS.LABCORP - ISSUED STATEMENT REGARDING COURT DECISION TO DISMISS LAWSUIT TO HALT IMPLEMENTATION OF DAMAGING CUTS TO MEDICARE REIMBURSEMENT FOR LAB TESTING.LABCORP - EVALUATING OPTIONS ALONGSIDE INDUSTRY ASSOCIATION ACLA & COLLEAGUES TO "HELP PROTECT MEDICARE BENEFICIARIES' CONTINUED ACCESS TO NEEDED LAB TESTING".  Full Article

LabCorp Launches Proprietary UltraQual Multiplex PCR Assay For HCV, HIV-1, HIV-2 And HBV
Wednesday, 27 Jun 2018 08:45am EDT 

June 27 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP LAUNCHES PROPRIETARY ULTRAQUAL® MULTIPLEX PCR ASSAY FOR HCV, HIV-1, HIV-2 AND HBV.LABCORP - RECEIVED APPROVAL FROM U.S. FDA FOR ULTRAQUAL MULTIPLEX PCR ASSAY FOR HCV, HIV-1, HIV-2 AND HBV FOR SCREENING OF DONATED BLOOD PLASMA.  Full Article

UnitedHealthcare Renewed Strategic Partnership With LabCorp
Thursday, 24 May 2018 04:30pm EDT 

May 24 (Reuters) - Laboratory Corporation of America Holdings ::UNITEDHEALTHCARE ESTABLISHES LONG-TERM STRATEGIC PARTNERSHIP WITH LABCORP.LABCORP - CO, UNITEDHEALTHCARE HAVE RENEWED THEIR LONG-TERM STRATEGIC PARTNERSHIP.  Full Article

Eurofins Scientific Acquires LabCorp's Food Testing And Consulting Business
Monday, 30 Apr 2018 01:46am EDT 

April 30 (Reuters) - EUROFINS SCIENTIFIC SE ::ACQUISITION OF LABCORP’S FOOD TESTING AND CONSULTING BUSINESS.TRANSACTION EXPECTED TO CLOSE IN Q3 OF 2018.AGREED ACQUISITION PRICE IS US$670M ON A CASH FREE DEBT FREE BASIS.  Full Article

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 08:45am EST 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​
Wednesday, 1 Nov 2017 08:45am EDT 

Nov 1 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​.  Full Article

LabCorp reports Q3 adjusted earnings per share of $2.46
Wednesday, 25 Oct 2017 06:55am EDT 

Oct 25 (Reuters) - Laboratory Corporation Of America Holdings :LabCorp announces record third quarter results and increases 2017 guidance.Q3 adjusted earnings per share $2.46.Q3 earnings per share $1.74.Q3 revenue $2.6 billion versus I/B/E/S view $2.55 billion.Q3 earnings per share view $2.39 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $9.40 to $9.60.LabCorp - ‍backlog for covance drug development at end of quarter was $6.84 billion, which includes backlog from Chiltern acquisition of $1.0 billion ​.LabCorp - ‍expects approximately $2.7 billion of backlog in covance drug development to convert into revenue in next twelve months​.LabCorp - ‍sees 2017 free cash flow increased to $970 million to $1,010 million, up 8% to 13% over 2016​.LabCorp sees ‍for 2017 net revenue growth of 8.0% to 8.5% over 2016 net revenue of $9.44 billion​.FY2017 earnings per share view $9.50, revenue view $10.10 billion -- Thomson Reuters I/B/E/S.LabCorp says "‍revenue growth" in quarter "was negatively impacted by approximately 0.7% due to multiple hurricanes during quarter​".  Full Article

UPDATE 1-Eurofins Scientific raises outlook after acquisitions, Q3 growth

Oct 23 Luxembourg-based food and biopharma product testing firm Eurofins Scientific raised its earnings expectations for 2019 and 2020 for the second time this year on Tuesday following acquisitions and a strong third quarter.